【摘要】 患者女,69岁,高血压病病史10年,既往无糖尿病病史,于2003年4月开始口服吲达帕胺,服药前血糖4.2mmol/L。2012年12月体检测FPG 8.5mmol/L,后连续两日复查FPG分别为7.2、7.9mmol/L,诊断为糖尿病。未行饮食及降糖药物治疗,停服吲达帕胺1周后复查2次FPG分别为5.4、5.3mmol/L,1个月后复查FPG为4.9mmol/L。长期口服吲达帕胺可诱发糖尿病,且吲达帕胺对患者的糖代谢损害是可逆的。更多还原

【Abstract】 A 69 years old female patient with a history of hypertension for 10 years without history of diabetes began a long-term oral indapamide therapy from April of 2003 to 2013.His fasting blood glucose before the therapy was 4.2 mmol/L.In December of 2012,his fasting blood glucose was 8.5mmol/L.We re-examined fasting blood glucose were 7.2and 7.9mmol/L in the consecutive days.The patient was diagnosed as diabetes.One week after stopping the indapamide and without diet and hypoglycemic drug therapies,the fasting blood glucose was 5.4,5.3mmol/L.And it was 4.9mmol/L after one more month.The above suggests that long-term oral indapamide may induce hyperglycemia and even diabetes.And the influence of indapamide on the glucose metabolism is reversible.更多还原